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Abstract: Milk and dairy products are known to contain various bioactives with potential
anti-inflammatory and immune modulating effects. Previous research has indicated that milk
produced from hyperimmunized cows provided meaningful health benefits to individuals suffering
from varying degrees of osteoarthritis and rheumatoid arthritis. PURPOSE: To examine the impact
of a proprietary milk protein concentrate on joint discomfort and physical function, exercise
performance, quality of life and various measures of affect. METHODS: Non-osteoarthritic men (42.5
± 8.9 years, 176.7 ± 6.7 cm, 89.9 ± 11.5 kg, 28.8 ± 3.5 kg/m2 , n = 30) and women (46.4 ± 9.6 years,
163.1 ± 8.2 cm, 72.2 ± 13.1 kg, 27.2 ± 5.3 kg/m2 , n = 28) with mild to moderate knee pain during
physical activity were randomized in a double-blind, placebo-controlled fashion to consume daily
either a placebo (PLA) or a proprietary milk protein concentrate (MP) for a period of 8 weeks.
Participants completed a functional capacity test pre and post-supplementation and completed visual
analog scales (VAS), a 6-min walking test, WOMAC and profile of mood states (POMS) to assess
changes in joint health, discomfort, physical function, exercise performance and affect. Mixed factorial
ANOVA was used for all statistical analysis and significance was set a priori at p ≤ 0.05. RESULTS:
Distance covered in the 6-min walking significantly improved 9% in MP versus 2% in PLA (mean
difference: 110 ± 43 m, p = 0.012) in addition to 11 WOMAC components and 5 VAS reflective of MP
improving joint health, discomfort and joint stability (all p < 0.05 vs. PLA). Additionally, MP also
improved overall perceptions of neck and back health compared to PLA. Serum and whole blood
indicators of clinical safety remained within normal ranges throughout the study. CONCLUSIONS:
In comparison to placebo, daily doses of proprietary milk protein concentrate yielded improvements
in several components of the WOMAC, multiple visual analog scales indicative of joint health and
stability, discomfort and pain, as well as significant improvements in distance covered during a 6-min
walking test. Supplementation was well tolerated with no significant changes in whole-blood or
serum markers of clinical safety.
Keywords: milk; protein; immunity; inflammation; concentrate; joint health; osteoarthritis

1. Introduction
According to the results of a National Health Interview Survey released in 2015, approximately
91 million people have some form of arthritis [1]. Of the different forms of arthritis, osteoarthritis
is the most common joint disorder in the United States with approximately 10% of men and 13%
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of women over 60 years of age having symptomatic knee osteoarthritis [2,3]. By the year 2030, it is
estimated that 20% of U.S. Americans (approximately 70 million people) will reach the age of 65, the
point of increased risk of osteoarthritis. Key symptoms associated with osteoarthritis include the
onset of pain, development of various disabilities such as increased difficulty with climbing stairs,
walking and other activities of daily living [4,5]. As such, the combination of advancing age in the
population and the established prevalence of pain-related symptoms and lost productivity results
in the need for primary and secondary means to alleviate pain and improve function [6]. In this
respect, pharmacological approaches and non-steroidal anti-inflammatory drugs (NSAIDS) including
acetaminophen, ibuprofen and naproxen are commonly considered [7]. In addition to prescription
and non-prescription medications, several nutraceuticals are commonly considered for their ability
to mitigate pain (discomfort) and inflammation including glucosamine, chondroitin, hyaluronic acid,
calcium, omega-3 fatty acids, olive oil and curcumin [8]. Beyond these approaches, several studies
have highlighted milk from hyper-immunized cows, for their ability to bolster immunity and promote
anti-inflammation [9–12]. Additionally, both human and bovine milk are known to contain many
bioactive factors [13] while hydrolyzing casein and whey (proteins found in milk) yields several
bioactive peptides with a diverse array of biological functions/effects, including opioid agonists
and antagonists, antimicrobial, anti-inflammatory, immune modulations and nutrient transport
systems [14].
Previous research has shown that the ingestion of skim milk powder from hyperimmunized
cows can reduce cholesterol [9] and inflammation [10,11]. While initial outcomes were positive
(improved ratings of QOL, energy, general well-being and sleep quality in over 60% of the 3500 people
surveyed), the open-label, cross-sectional nature of the original report [15], impracticality of dosing
and inconvenience associated with poor mixing and palatability stymied additional investigation.
To address these shortcomings, a proprietary (lactose-free) milk protein concentrate was developed
from milk produced in hyperimmunized cows retaining much of the valuable high-molecular weight
immunoglobulins and low-molecular weight bioactives while removing much of the carbohydrate,
salt and fat resulting in its ability to be concentrated and encapsulated. To examine its effects,
Colker et al. [16] had 31 adults with physician diagnosed osteoarthritis in their knees supplement in
a randomized, double-blind fashion with either a placebo or concentrated milk protein. Before and
after supplementation, participants completed visual analog scales for pain, physical function and
quality of life while also completing the Western Ontario and McMaster Universities Osteoarthritis
Index (WOMAC). A significant treatment effect was observed in the WOMAC, knee pain, sport
function and quality of life for those participants who consumed the concentrated milk protein while
only improvements in sport function and quality of life were found in the placebo group. Additional
research by Zenk et al. [17] investigated the impact of ingesting a concentrated milk protein from
hyperimmunized cows in 35 men and women (range: 34–86 years) diagnosed with osteoarthritis
who were supplemented in a randomized, double-blind fashion to ingest either concentrated milk
protein (two daily doses of 2000 mg), glucosamine sulfate (three daily doses of 500 mg) or a placebo
for a six-week period. In this study, osteoarthritis symptoms were again assessed using the WOMAC.
As seen with the Colker study, those individuals who supplemented with a concentrated milk protein
from hyperimmunized cows reported a significant reduction in all four scores of the WOMAC
(i.e., stiffness, discomfort, physical function and total score). Glucosamine supplemented participants
experienced significant reductions in two of the four scores (stiffness and total WOMAC) while no
changes were reported in the placebo group.
Research to date on ingestion of concentrated milk proteins from milk produced by
hyperimmunized cows has been limited to individuals with osteoarthritis. In addition, while the
Zenk [17] and Colker [16] findings are valuable due to the randomized, double-blind, placebo
controlled study approach they employed, both studies recruited relatively small sample sizes
(n = 10–15 per group) and failed to examine if supplementation can improve performance of a physical
task and if pain or discomfort associated with completing that task was reduced. Furthermore,
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beyond markers of clinical safety, neither study reported on any biomarkers that might help to
offer any insight into potential mechanism(s) of action. Therefore, the purpose of this study was
to examine the impact of ingesting a concentrated milk protein derived from the milk produced by
hyperimmunized cows on alleviating pain (discomfort) and function with and without an external
physical stimulus in non-osteoarthritic participants who reported having mild to moderate functional
knee pain during/after physical activity. We also sought to examine changes in physical performance
and a biomarker of cartilage breakdown.
2. Methods
2.1. Overview of Study Design
The study was a randomized, double-blind, placebo-controlled investigation using two parallel
supplementation groups that spanned eight weeks. Each participant completed four study visits. The first visit
was for screening purposes and consisted of signing an IRB-approved consent form, completing a medical
history, recording their diet information, completing the functional capacity test and visual analog scales
and having routine blood work (CMP, CBC, lipid panel) completed. Prior to the screening visit, participants
were confirmed to have stopped, for the previous four weeks, the use of over-the-counter medicines for pain
or inflammation, including non-steroidal anti-inflammatory drugs (NSAIDS), acetaminophen and full-dose
aspirin (325 mg). At regular four-week intervals, study participants completed three additional study visits
(0, 4 and 8 weeks) and were assessed for dietary habits, physical activity (Framingham Physical Activity
Index), adverse events, profile of mood states (POMS), joint pain and health (WOMAC) and various visual
analog scales to assess fatigue/energy, mood, quality of training and motivation to exercise. In addition,
participants completed a functional capacity test as a part of visits 3 (week 4) and 4 (week 8). To evaluate
clinical safety, participants had hemodynamic, complete blood counts, comprehensive metabolic and lipid
panels completed during visits 1 (week 0) and 4 (week 8). Prior to all study visits, participants were asked
to replicate their previous 24-hr dietary intake, avoid alcohol for 24 h, abstain from exercise for 48 h and fast
for ten hours. To control for diurnal variations, all study visits were completed in the morning (700–1200)
with all follow-up visits being scheduled at a similar time as initial visits. Upon completion of visits 2 and 3,
participants were provided with study product. Table 1 provides a general layout of all testing. This clinical
trial did not evaluate a drug, biological product or medical device and consequently was not required to be
registered at Clinicaltrials.gov prior to its initiation.
Table 1. Overview of Research Design.
Procedure

Visit 1
Screening

Visit 2
(Week 0)

Visit 3
(Week 4)

Visit 4
(Week 8)

Informed Consent

X

COMP (Cartilage breakdown biomarker)

X

X

X

Inclusion/Exclusion Criteria

X

Medical History

X

Physical Exam

X

Height and weight

X

Vitals (HR, BP)

X

Blood Analyses (CBC, CMP w/lipids)

X

X

WOMAC scales

X

X

X

3 Day Diet Records

X

X

X

Profile of Mood States

X

X

X

Visual Analog Scales

X

X

X

X

X

Physical Activity

X

Functional Capacity Test

X

X

Protocol Compliance (pill counts)
Adverse Events Monitoring

X

X

X

X

X

X

X

X = procedure performed; BP = Blood pressure; HR = heart rate; CMP = Comprehensive metabolic panel; CBC =
Complete blood counts; COMP = Cartilage oligometric matrix protein.
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2.2. Study Participants
Male (42.5 ± 8.9 years, 176.7 ± 6.7 cm, 89.9 ± 11.5 kg, 28.8 ± 3.5 kg/m2 , n = 30) and female
(46.4 ± 9.6 years, 163.1 ± 8.2 cm, 72.2 ± 13.1 kg, 27.2 ± 5.3 kg/m2 , n = 28) study participants
between the ages of 35–70 years were recruited from the local community (Table 2). Prior to any
data collection, all subjects gave their informed consent for inclusion before they were enrolled
into the study. The study was conducted in accordance with the Declaration of Helsinki and the
protocol was approved by the Ethics Committee of Integreview (Integreview, Austin, TX; protocol #
SMB001-2017, approval date: December 13, 2017). Study participants were pre-screened using health
history questionnaires, had vital signs assessed and a physical exam was completed by a physician.
Eligible study participants were those individuals who were free of disease, including osteoarthritis,
between the ages of 35–70 years, non-smokers, meeting minimum physical activity recommendations
and had a body mass index between 27–45 kg/m2 at screening. All participants were required to
self-report no knee joint discomfort at rest and ‘mild-to-moderate or higher’ (defined as a rating of
30/100 or higher on a 100-mm visual analog scale for knee discomfort) with activity or exercise over
the last three weeks. Females were required to not be pregnant or currently lactating and agree to
use an effective contraceptive method during the study. Changes in menstrual cycle were viewed
to be minimal due to each study visit being eight weeks apart. Each visit was scheduled at similar
times of the day to further help control for any diurnal variations. Participants were excluded if they:
were already diagnosed with having some form of inflammatory disorder or osteoarthritis, currently
taking some form of anti-inflammatory nutritional supplement, had received any form of intraarticular
injection (glucocorticoid, hyaluronic acid, bone marrow, platelet rich plasma, etc.) within six months of
enrolling in study, reported daily use of a non-steroidal anti-inflammatory drug, were determined to
have anemia or another form of nutritional deficiency, psychiatric illness, GI disorder, allergic reactions
to bovine milk or other food allergies or intolerances or abnormal vital signs (systolic blood pressure:
<90 or >150 mm Hg, diastolic blood pressure: <50 or >100 mm Hg, heart rate: <50 or >110 beats
per minute).
Table 2. Baseline Demographics, WOMAC Scores and Dietary Data.
MP (n = 24)

PLA (n = 34)

Sig.

41.1 ± 10.0 (n = 11)
48.5 ± 7.9 (n = 13)

43.3 ± 8.4 (n = 19)
44.3 ± 10.7 (n = 15)

0.54

Height (centimeters)
Males
Females

179.4 ± 3.1
164.7 ± 7.7

175.2 ± 7.8
161.7 ± 8.6

0.42

Body Mass (kilograms)
Males
Females

93.9 ± 12.1
73.1 ± 12.4

87.6 ± 10.8
71.4 ± 14.0

0.59

Body Mass Index (kg/m2 )
Males
Females

29.1 ± 3.5
27.2 ± 5.3

28.6 ± 3.5
27.5 ± 6.3

0.89

Systolic Blood Pressure (mm Hg)
Males
Females

123.3 ± 10.1
113.8 ± 12.8

126.9 ± 8.8
114.8 ± 12.1

0.29

79.9 ± 6.6
73.3 ± 9.3

77.3 ± 8.1
72.0 ± 9.4

0.57

Age (years)
Males
Females

Diastolic Blood Pressure (mm Hg)
Males
Females
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Table 2. Cont.
MP (n = 24)

PLA (n = 34)

Sig.

69.6 ± 14.3
65.9 ± 8.8

66.9 ± 11.0
65.8 ± 8.2

0.70

587.9 ± 146.2
547.5 ± 69.6

623.3 ± 133.7
544.4 ± 87.3

0.47

WOMAC Total Stiffness
Males
Females

2.91 ± 1.22
3.39 ± 1.04

3.21 ± 1.23
3.20 ± 1.15

0.90

WOMAC Physical Function
Males
Females

21.6 ± 11.4
18.2 ± 9.2

23.5 ± 10.0
17.2 ± 7.1

0.70

WOMAC Overall Total
Males
Females

30.6 ± 15.1
26.0 ± 9.9

33.4 ± 13.6
27.3 ± 11.8

0.71

Resting HR (beats/min)
Males
Females
6-Minute Walk Test (meters)
Males
Females

MP = proprietary milk protein concentrate; PLA = placebo. Sig. = p-value for between-group difference using
independent t-test with genders collapsed within each group. Mm Hg = millimeters of mercury; kg = kilograms; m2
= meters squared; WOMAC = Western Ontario & McMaster Universities Osteoarthritis Index.

2.3. Demographics
Standing height was determined using a wall-mounted stadiometer with each study participant
in socks with their heels together. Body weight was measured using a Seca 767™ Medical Scale
(Hamburg, Deutschland). Resting heart rate and blood pressure was measured in duplicate using an
automated blood pressure cuff (Omron HEM-780).
2.4. Venous Blood Collection
Whole blood and serum samples were collected using standard phlebotomy techniques during
all study visits after participants observed a ten hour fast. All collected samples were processed
immediately for analysis at a central clinical chemistry laboratory (LabCorp) while a portion of
remaining sample was stored at −80 ◦ C for any remaining analyses. Whole blood samples were
collected into K2 -EDTA treated Vacutainer tubes and upon collection were slowly inverted ten
consecutive times prior to immediate refrigeration. Serum samples were collected in non-treated
tubes and allowed to clot for 30 min at room temperature prior to being centrifuged (Horizon mini
E Centrifuge, Drucker Diagnostics, Port Matilda, PA) for 15 min at 3200 rpm (1500× g). Serum was
extracted from all samples and aliquots were pipetted into cryovial storage tubes. All blood samples
were analyzed for clinical chemistry analysis (plasma glucose, blood urea nitrogen (BUN), creatinine,
aspartate aminotransaminase (AST), alanine aminotransaminase (ALT), creatine kinase, lactate
dehydrogenase, total bilirubin, alkaline phosphatase (ALP), triacylglycerol (TG), total cholesterol
[TC], LDL-C, HDL-C, uric acid, sodium, potassium, total protein, albumin, globulin, iron, complete
blood cells and platelet count). All samples from the same day were batch analyzed with test-retest
reliabilities commonly reported using internal quality control data from clinical laboratories and
associated automated analyzers within a range of 3–5% [18]. Serum levels of cartilage oligomeric
matrix protein (COMP) were analyzed in duplicate using standard ELISA techniques. The test-retest
reliability coefficient for this assay was <10%.
2.5. Functional Capacity
Functional capacity was assessed using a standardized protocol as part of screening and again
at week 4 and week 8. After completing a basic warm-up consisting of ten minutes of whole-body
stretches and callisthenic movements, study participants performed three sets of 10–12 repetitions of
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leg extension exercise. These repetitions were completed as an attempt to pre-fatigue the involved
musculature. The load was assigned to yield an RPE level of at least an 8 (out of 10) during the
completion of the last two repetitions of each set. Load was adjusted after the first set of repetitions if
a minimum RPE of 7 (out of 10) was not reported. Two minutes of rest were provided between each
set. Upon completing the third set, study participants were required to complete a 6-min walk test
at a self-selected maximal walking velocity. Prior to commencing the test, study participants were
informed of the course layout and instructed to walk as far and as fast as they could for the six-minute
duration of the test.
2.6. Visual Analog Scales and Questionnaires to Assess Affect and Joint Health
Visual analog scales (VAS) were completed by study participants at baseline, week 4 and week 8.
All VAS were constructed similarly with a 100-mm line anchored by “Lowest Possible” and “Highest
Possible” to assess subjective ratings of joint discomfort, knee mobility, knee stability, low-back
health, neck mobility and whole-body joint health. The validity and reliability of VAS to assess
fatigue and energy have been previously established [19]. At each study visit, the profile of mood
states (POMS) was administered. The POMS consist of a series of five item questions (0—Not At
All, 1—A little, 2—Moderately, 3—Quite a Lot, 4—Extremely) associated with negative (tension,
depression, fatigue, confusion and anger) and positive (vigor, esteem) feelings to determine a total
score. Additionally, participants were administered the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC). Subscale totals for discomfort, stiffness, physical function as well as
a total score were computed.
2.7. Dietary Intake and Physical Activity
Participants were asked to maintain their current energy and macronutrient intake throughout
the entire study protocol. During the initial screening visit, participants were asked to complete a 24-h
dietary recall to assess general dietary habits, food restrictions, diet composition and quantity of intake.
Additionally and as the study progressed, three-day dietary records were completed prior to visits two
(baseline), three (week 4) and four (week 8) to track dietary compliance. Dietary records were analyzed
for average daily energy and macronutrient intake by trained study investigators and NutriBase IX
(Clinical Edition) software (CyberSoft, Inc. Phoenix, AZ, USA). Copies of food records were made
and provided to each study participant to allow them to standardize their dietary and fluid intake
24 h prior to each study visit. At each study visit, a research team member asked each participant
a series of questions using the Framingham Physical Activity Index regarding sleep, occupational and
non-occupational activities to assess physical activity status [20,21].
2.8. Supplementation
In a randomized, double-blind fashion, all study participants were assigned to orally ingest,
on a daily basis, either a placebo (microcrystalline cellulose) or 4000 milligrams of a proprietary milk
protein concentrate from hyperimmunized cows. Both products were provided in opaque “00” sized
capsules. Subjects took one dose (5 capsules totaling 2000 mg) in the morning and one dose (5 capsules
totaling 2000 mg) in the evening with 12 fluid ounces of cold tap water. Supplement purity and potency
was confirmed by a third party (independent) laboratory. All randomization was completed using an
online randomization program. (www.randomizer.org).
2.9. Adverse Events
During weekly phone calls, the frequency and intensity of local and systemic non-serious and
serious adverse events (AEs) were recorded by study team members. All reported events were coded
using the Medical Dictionary for Regulatory Activities (MedDRA) while the intensity of recorded
adverse events were graded using standardized criteria.
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2.10. Statistical Analysis
All data were entered into Microsoft Excel (Seattle, WA, USA) software and analyzed using IBM
SPSS 23 (Armonk, NY, USA). A priori power analysis and sample size determination was based on
previous studies using the WOMAC [16,17]. For these calculations, an estimated mean difference of
4.5 for total WOMAC score was assumed to be a meaningful change in the MP group in comparison
to the changes observed in the PLA group. With an alpha level of 0.05 and power set at 0.80, it was
determined a sample size of 30 participants (SD = 10) were needed per group. Normality assumptions
were checked on all variables using a one-sample Shapiro-Wilk test. Many variables assessed using
VAS, POMS and WOMAC were found to be non-normally distributed. In these instances, findings were
assessed first using Mann-Whitney U and when significant between-group differences were realized,
Wilcoxon signed rank tests were completed to evaluate differences between time points. Due to the
known robustness of the ANOVA and to aid in understanding identified changes, all non-normally
distributed data was transformed using log10 and was subsequently presented and analyzed using
parametric approaches. For example, independent t-tests were used to assess baseline differences.
Data were initially analyzed using a 3-way mixed factorial ANOVA (gender x group × time) to assess
gender specific responses in each group across time, however, no gender-specific outcomes were noted.
While some key variables approached significance, none reached the a priori statistical threshold of
0.05. Consequently, all remaining data were analyzed using a 2 × 2 mixed factorial ANOVA (group
(placebo vs. MP) × time (0 vs. 8 weeks)) with repeated measures on time to determine the presence
of any main (time or group) and interaction (group × time) effects. No midpoint (4-week) analysis
was computed due to an a priori determination to assess changes in dependent variables after eight
weeks of supplementation. When the sphericity assumption was not met, the Huynh-Feldt correction
was applied. Group × time interaction effects were decomposed using independent samples t-test
using the calculated delta (Week 8–Week 0). Mean difference of the change scores and 95% confidence
intervals were calculated on the difference between groups using delta values. Within-group effects
were compared using paired samples t-test. Outliers were checked via visual inspection of studentized
calculations on the residuals (threshold value of ± 3) of each dependent variable. Effects were
considered significant at P ≤ 0.05 and trends were declared at 0.05 ≤ P ≤ 0.10. Effect sizes (eta squared)
are also reported, using 0.01, 0.06, and 0.14 to represent small, medium and large effects, respectively.
3. Results
No baseline differences (p > 0.05) were noted between groups or between gender (sex) for any
of the demographic variables (age, height, body mass, body mass index, blood pressure (systolic &
diastolic), resting heart rate, 6-min walk test performance, WOMAC total stiffness, WOMAC physical
function and WOMAC total score) (Table 2). One participant assigned to the placebo group experienced
a gastrointestinal hemorrhage while enrolled in the study protocol. No other adverse events were
reported for any other participants enrolled in the study (see Figure 1).
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Figure 1. Consolidated Standards of Reporting Trials (CONSORT) diagram.

3.1. Dietary and Physical Activity Data
No significant main effect for time or group × time interaction effects were identified for any of the
dietary data. Caloric intake was determined to be (PLA: 1,728 ± 502, MP: 1578 ± 413 kcals/day) and
(PLA: 1819 ± 645, MP: 1581 ± 519 kcals/day) for visits week 0 and week 8, respectively. The main effect
for time (p = 0.56) and the group × time interaction effect (p = 0.46) were not statistically significant.
Carbohydrate intake was determined to be (PLA: 195 ± 75, MP: 160 ± 54 g/day) and (PLA: 199 ± 89,
MP: 163 ± 56 g/day) for week 0 and week 8, respectively. The main effect for time (p = 0.38) and the
group × time interaction effect (p = 0.99) were not statistically significant. Fat intake was determined
to be (PLA: 68 ± 21, MP: 69 ± 26 g/day) and (PLA: 73 ± 46, MP: 65 ± 26 g/day) for week 0 and week
8, respectively. The main effect for time (p = 0.59) and the group × time interaction effect (p = 0.46)
were not statistically significant. Protein intake was determined to be (PLA: 87 ± 28, MP: 80 ± 25
g/day) and (PLA: 91 ± 37, MP: 77 ± 25 g/day) for week 0 and week 8, respectively. The main effect
for time (p = 0.27) and the group × time interaction effect (p = 0.44) were not statistically significant.
Additionally, when macronutrient intake was expressed as a percentage of total calories consumed, no
significant differences were noted for all macronutrients between groups across the duration of the
study. Framingham physical activity index values were assessed at baseline (PLA = 38.6 ± 8.9 vs. MP
= 37.7 ± 9.2, p = 0.71) and after completion (PLA: 38.9 ± 9.7 vs. MP: 38.0 ± 10.0, p = 0.75) of the study
protocol. Additionally, no significant group × time interaction effect was found (p = 0.97). Intraclass
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correlation coefficient of the PLA group across all measurements timepoints were determined for total
calorie (95% CI: 0.713–0.869), carbohydrate (95% CI: 0.786–0.906), fat (95% CI: 0.327–0.629) and protein
(95% CI: 0.627–0.823) intake as well as Framingham Physical Activity Index (95% CI: 0.914–0.964).
3.2. WOMAC Data
Eleven WOMAC variables exhibited significant group × time interaction effects that favored
the MP group: Physical Function – Descending Stairs (p = 0.02; 95% CI: 0.09, 1.17), Physical
Function—Standing (p = 0.03; 95% CI: 0.05, 0.76), Physical Function—Getting in Car (p = 0.002; 95% CI:
0.25, 1.04), Physical Function—Shopping (p = 0.004; 95% CI: 0.20, 0.96), Physical Function—Putting on
Socks (p = 0.002; 95% CI: 0.25, 1.04), Physical Function—Removing Socks (p = 0.002; 95% CI: 0.23, 1.00),
Physical Function—Moving in Bed (p = 0.002, 95% CI: 0.21, 0.91), Physical Function—Getting In and Out
of Bed (p = 0.005, 95% CI: 0.15, 0.78), Physical Function, Getting On and Off the Toilet (p = 0.011, 95% CI:
0.11, 0.80), Physical Function Total Score (p = 0.004, 95% CI: 2.8, 13.3) and WOMAC Total Score (p = 0.01,
95% CI: 2.5, 17.4). Percent improvement was 35% in overall joint health (Total WOMAC score) with MP
compared to no change in PLA (~1% decrease). Physical function (i.e., mobility) improved 39% with
MP compared to a 1% improvement in PLA. Other markers of physical function (i.e., shopping, getting
in and out of bath, putting on socks, moving in bed, etc.) in the MP group experienced improvements
of 48–60% compared to 3–17% improvements in PLA. In addition, five additional variables approached
the statistical threshold for a statistically significant group × time interaction effect (p = 0.05–0.10).
These variables included: Physical Function – At Night While in Bed (p = 0.054, 95% CI: −0.007, 0.79),
Physical Function—Ascending Stairs (p = 0.062, 95% CI: (−0.03, 1.11), Physical Function—Rising to
Sitting (p = 0.08, 95% CI: −0.06, 0.96), Physical Function—Walking on Flat Surface (p = 0.09, 95% CI:
−0.06, 0.86) and Physical Function—Sitting (p = 0.074, 95% CI: −0.03, 0.71). All WOMAC data can be
found in Table 3. Changes in total WOMAC scores are shown in Figure 2.
Table 3. WOMAC Data.
Variables

n

Baseline

Post

Within
p Value

Between-Group Comparison
Mean Difference †

PLA
MP

34
24

1.50 ± 0.66
1.54 ± 0.78

WOMAC Stiffness—In Morning
1.35 ± 0.81
0.30
0.311
1.08 ± 0.50
0.005

PLA
MP

34
24

1.71 ± 0.68
1.63 ± 0.65

WOMAC Stiffness—After Being Immobile
1.50 ± 0.96
0.21
0.127
1.29 ± 0.81
0.043

PLA
MP

34
24

3.21 ± 1.18
3.17 ± 1.13

WOMAC Total Stiffness Score
2.85 ± 1.62
0.20
0.439
2.38 ± 1.10
0.004

PLA
MP

34
24

1.12 ± 0.64
0.96 ± 0.75

WOMAC Discomfort—Walking on Flat Surface
1.12 ± 0.81
0.99
0.333
0.63 ± 0.65
0.043

PLA
MP

34
24

2.00 ± 0.65
1.96 ± 0.81

WOMAC Discomfort—Going Up or Down Stairs
1.82 ± 1.14
0.42
0.281
1.50 ± 0.83
0.02

PLA
MP

34
24

0.91 ± 0.71
1.04 ± 0.91

WOMAC Discomfort—At Night While in Bed
0.97 ± 0.90
0.64
0.392
0.71 ± 0.69
0.04

PLA
MP

34
24

1.00 ± 0.78
0.88 ± 0.80

WOMAC Discomfort—Sitting or Lying
0.94 ± 0.89
0.69
0.108
0.30
0.71 ± 0.69

PLA
MP

34
24

1.15 ± 0.86
1.08 ± 0.50

WOMAC Discomfort—Standing Upright
1.12 ± 0.88
0.85
0.346
0.71 ± 0.69
0.004

95% CI

p Value

(−0.11, 0.73)

0.14

(−0.34, 0.59)

0.59

(−0.32, 1.20)

0.25

(−0.10, 0.77)

0.13

(−0.33, 0.89)

0.36

(−0.007, 0.79)

0.054

(−0.33, 0.54)

0.62

(−0.07, 0.77)

0.11
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Table 3. Cont.
Variables

n

Baseline

Post

Within
p Value

Between-Group Comparison
Mean Difference †

WOMAC Total Discomfort Score
5.97 ± 4.20
0.76
1.46
4.25 ± 2.58
0.006

PLA
MP

34
24

6.18 ± 2.95
5.92 ± 2.75

PLA
MP

34
24

1.71 ± 0.63
1.71 ± 1.04

WOMAC Physical Function—Descending Stairs
1.79 ± 1.20
0.65
0.630
1.17 ± 0.92
0.004

PLA
MP

34
24

1.68 ± 0.77
1.75 ± 0.79

WOMAC Physical Function—Ascending Stairs
1.68 ± 1.15
0.99
0.54
1.21 ± 0.88
0.02

PLA
MP

34
24

1.35 ± 0.73
1.39 ± 0.72

WOMAC Physical Function—Rising to Sitting
0.70
1.41 ± 0.82
0.45
1.00 ± 0.74
0.08

PLA
MP

34
24

0.97 ± 0.81
0.96 ± 0.69

WOMAC Physical Function—Standing
1.00 ± 0.90
0.79
0.41
0.58 ± 0.58
0.02

PLA
MP

34
24

1.44 ± 0.66
1.17 ± 0.82

WOMAC Physical Function—Bending to Floor
1.35 ± 0.92
0.61
0.33
0.02
0.75 ± 0.74

PLA
MP

34
24

WOMAC Physical Function—Walking on Flat Surface
1.00 ± 0.82 0.94 ± 0.89
0.71
0.40
0.92 ± 0.78 0.46 ± 0.59
0.008

PLA
MP

34
24

1.09 ± 0.75
1.13 ± 0.85

WOMAC Physical Function—Getting in Car
1.24 ± 0.96
0.28
0.65
0.001
0.63 ± 0.71

PLA
MP

34
24

0.97 ± 0.76
0.87 ± 0.87

WOMAC Physical Function—Shopping
1.03 ± 0.90
0.62
0.58
0.35 ± 0.49
0.002

PLA
MP

34
24

0.88 ± 0.81
0.92 ± 0.83

WOMAC Physical Function—Putting on Socks
1.03 ± 0.87
0.23
0.65
0.42 ± 0.65
0.005

PLA
MP

34
24

1.09 ± 0.71
1.13 ± 0.68

WOMAC Physical Function—Rising from Bed
1.12 ± 0.88
0.83
0.32
0.83 ± 0.76
0.13

PLA
MP

34
24

0.94 ± 0.78
0.86 ± 0.83

WOMAC Physical Function—Removing Socks
1.06 ± 0.92
0.33
0.62
0.36 ± 0.58
0.005

PLA
MP

34
24

0.85 ± 0.74
1.04 ± 0.95

WOMAC Physical Function—Moving in Bed
0.91 ± 0.90
0.60
0.56
0.54 ± 0.72
0.001

PLA
MP

34
24

WOMAC Physical Function—Getting In and Out of Bath
0.97 ± 0.76 1.00 ± 0.85
0.77
0.46
0.78 ± 0.80 0.35 ± 0.57
0.002

PLA
MP

34
24

0.88 ± 0.73
0.83 ± 0.82

PLA
MP

34
24

WOMAC Physical Function—Getting On and Off of Toilet
1.00 ± 0.75 1.12 ± 0.96
0.33
0.45
0.83 ± 0.82 0.50 ± 0.72
0.008

PLA
MP

34
24

WOMAC Physical Function—Heavy Domestic Tasks
2.15 ± 0.70 1.97 ± 1.09
0.33
0.28
1.96 ± 0.75 1.50 ± 0.72
0.02

PLA
MP

34
24

1.79 ± 0.70
1.50 ± 0.66

PLA
MP

34
24

20.7 ± 9.3
19.8 ± 10.2

WOMAC Physical Function Total Score
21.0 ± 13.8
0.87
8.0
12.0 ± 8.6
<0.001

PLA
MP

34
24

30.1 ± 12.5
28.8 ± 13.2

29.9 ± 19.4
18.6 ± 11.7

WOMAC Physical Function—Sitting
0.97 ± 0.90
0.48
0.34
0.58 ± 0.72
0.08

WOMAC Physical Function—Light Domestic Tasks
1.52 ± 1.09
0.20
0.44
0.79 ± 0.78
<0.001

WOMAC Total Score
0.92
<0.001

9.94

95% CI

p Value

(−0.40, 3.32)

0.12

(0.09, 1.17)

0.02 *

(−0.03, 1.11)

0.062

(−0.06, 0.96)

0.08

(0.05, 0.76)

0.03 *

(−0.16, 0.82)

0.18

(−0.06, 0.86)

0.09

(0.25, 1.04)

0.002 *

(0.20, 0.96)

0.004 *

(0.25, 1.04)

0.002 *

(−0.13, 0.77)

0.16

(0.23, 1.00)

0.002 *

(0.21, 0.91)

0.002 *

(0.15, 0.78)

0.005 *

(−0.03, 0.71)

0.074

(0.11, 0.80)

0.011 *

(−0.24, 0.80)

0.28

(−0.12, 0.99)

0.12

(2.8, 13.3)

0.004 *

(2.5, 17.4)

0.01 *

PLA = Placebo; MP = proprietary milk protein concentrate. 95% CI = 95% confidence interval of the difference
between MP and PLA. † Absolute difference in delta values between groups. Within p-value derived from factorial
ANOVA with repeated measures on time. Between-group p-values were calculated using independent t-tests using
the delta value (week 8–week 0). * indicates statistical significance.
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Figure 2. Changes in total WOMAC score after eight weeks of supplementation. The placebo group (n
= 34) reported an average decrease in total WOMAC score of −0.26 points. Of the 34 scores in the PLA
group, 12 (35.2%) scores experienced a reduction in their total WOMAC score more than the entire
study average. The proprietary milk protein concentrate group (n = 24) reported an average decrease in
total WOMAC score of 10.21 points. Of the 24 scores in the proprietary milk protein concentrate group,
15 (62.5%) scores decreased their total WOMAC score more than the entire study average. Dotted line
= average change in total WOMAC for entire study cohort. Black horizontal bars = average change in
total WOMAC for each study group.

3.3. Visual Analog Scales
Five variables exhibited a statistically significant group × time interaction favoring the MP group:
overall knee stability (p = 0.001), low back health (p = 0.002), neck health (p = 0.012), post-walk left
knee discomfort (p = 0.044) and pre-leg extension left knee discomfort (p = 0.03). In addition, post-walk
right knee discomfort approached significance (p = 0.09, effect size (d = 0.05)) but did not achieve
a statistically significant group × time interaction effect. Furthermore, when examining within-group
changes only the MP group reported any significant changes from the beginning to the end of the
study protocol and in all instances, assessments of pain or discomfort decreased while indicators of
health, stability or mobility improved (see Table 4).
Table 4. Visual Analog Scales to Assess Pain and Discomfort.
Variables

n

Baseline

Post

Within
p Value

Between−Group Comparison
Mean Difference †

95% CI

p Value

(−10.1, 4.8)

0.47

(−0.92, 1.45)

0.65

−0.92

(−2.09, 0.25)

0.12

−1.85

(−2.82, −0.88)

0.001 *

PLA
MP

34
24

7.4 ± 17.5
4.1 ± 2.9

Discomfort in Right Knee in Past 1–3 Weeks
3.6 ± 3.6
0.23
−2.68
3.1 ± 2.7
0.04

PLA
MP

34
24

3.2 ± 2.4
4.4 ± 2.5

Discomfort in Left Knee in Past 1–3 Weeks
2.3 ± 2.4
0.025
0.27
3.2 ± 2.7
0.01

PLA
MP

34
24

6.6 ± 1.9
6.8 ± 2.2

6.6 ± 2.1
7.6 ± 1.5

Knee Mobility
0.89
0.12

PLA
MP

34
24

6.5 ± 1.8
6.3 ± 2.0

6.5 ± 1.2
8.2 ± 1.0

Knee Stability
0.89
<0.001
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Table 4. Cont.
Variables

n

Baseline

Post

Within
p Value

Between−Group Comparison
Mean Difference †

95% CI

p Value

(−1.95, 0.23)

0.12

−1.78

(−2.90, −0.66)

0.002 *

−1.53

(−2.71, −0.36)

0.012 *

(−0.70, 1.27)

0.57

(−0.22, 1.73)

0.13

(−0.13, 1.64)

0.09

(0.03, 1.91)

0.044 *

(−0.17, 1.65)

0.11

(0.14, 2.08)

0.03 *

(−0.95, 1.42)

0.69

(−0.38, 1.91)

0.18

(−1.83, 1.75)

0.97

PLA
MP

34
24

6.4 ± 1.8
6.6 ± 1.9

Whole-Body Joint Health
6.9 ± 1.9
0.21
−0.86
7.9 ± 1.1
0.007

PLA
MP

34
24

6.6 ± 2.2
6.1 ± 1.9

6.3 ± 1.7
7.6 ± 1.6

Low-Back Health
0.35
0.009

PLA
MP

34
24

6.7 ± 1.8
6.3 ± 2.4

6.8 ± 1.8
8.0 ± 1.3

Neck Health
0.75
0.006

PLA
MP

34
24

3.4 ± 3.1
2.8 ± 2.7

Level of Right Knee Discomfort: Pre-Walk
3.6 ± 3.5
0.33
0.28
2.8 ± 2.5
0.99

PLA
MP

34
24

2.1 ± 1.9
3.2 ± 2.6

Level of Left Knee Discomfort: Pre-Walk
2.2 ± 2.3
0.87
0.75
2.5 ± 2.4
0.10

PLA
MP

34
24

3.8 ± 3.2
3.1 ± 3.0

Level of Right Knee Discomfort: Post-Walk
4.0 ± 3.6
0.58
0.76
2.5 ± 2.4
0.11

PLA
MP

34
24

2.5 ± 2.1
3.6 ± 2.5

Level of Left Knee Discomfort: Post-Walk
2.3 ± 2.6
0.58
0.97
2.5 ± 2.4
0.003

PLA
MP

34
24

3.8 ± 3.2
3.1 ± 3.0

Level of Right Knee Discomfort: Pre Leg Extension
4.0 ± 3.6
0.45
0.74
2.6 ± 2.5
0.19

PLA
MP

34
24

2.4 ± 2.2
3.6 ± 2.7

Level of Left Knee Discomfort: Pre-Leg Extension
2.3 ± 2.4
0.80
1.11
2.4 ± 2.3
0.003

PLA
MP

34
24

4.5 ± 3.4
4.2 ± 3.2

Level of Right Knee Discomfort: Post Leg Extension
4.1 ± 3.7
0.21
0.24
3.5 ± 3.0
0.21

PLA
MP

34
24

3.1 ± 2.6
4.7 ± 2.7

Level of Left Knee Discomfort: Post Leg Extension
2.5 ± 2.4
0.09
0.57
3.4 ± 2.7
0.01

PLA
MP

34
24

38.6 ± 8.9
37.7 ± 9.2

38.9 ± 9.7
38.0 ± 10.0

Framingham Score
0.59
0.69

−0.04

PLA = Placebo; MP = proprietary milk protein concentrate. 95% CI = 95% confidence interval of the difference
between MP and PLA. † Absolute difference in delta values between groups. Within p-value derived from factorial
ANOVA with repeated measures on time. Between-group p-values were calculated using independent t-tests using
the delta value (week 8–week 0). * indicates statistical significance.

3.4. Profile of Mood States
Of the 35 values recorded as part of the POMS assessment, the vigorous subset revealed
a significant (p = 0.02, 95% CI: −0.52, 0.28) group × time interaction. Follow-up within-group paired
samples t-tests revealed a significant reduction in the vigorous score in the MP group (Baseline:
1.63 ± 1.10 vs. Post: 1.13 ± 1.23, p = 0.03) while the placebo group exhibited no change (Baseline:
1.53 ± 1.05 vs. Post: 1.62 ± 0.95, p = 0.52). In addition, four other variables: energetic (p = 0.06, effect
size (d = 0.58)), confused (p = 0.08, effect size (d = 0.46)), helpless (p = 0.10, effect size (d = 0.44)) and
weary (p = 0.09, effect size (d = 0.47)) approached significance and in each instance, mean changes
revealed a favorable outcome for the MP group.
3.5. Exercise Performance
Significant group × time interaction effects were found for changes in 6-min walk test
performance, favoring the MP group (p = 0.012; 95% CI: (−60, −7.7). A significant within-group
change was observed for MP (Baseline: 566 ± 111 vs. Post: 614 ± 120 m, p < 0.001), which equated
to a 9% increase in distance walked while the PLA group experienced a 2% increase in performance
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(Baseline: 589 ± 121 vs. Post: 603 ± 122 m, p = 0.059). Changes in walk test performance are provided
in Figure 3.

Figure 3. Changes in performance of 6-min walk test after eight weeks of supplementation. The placebo
group (n = 34) reported an average increase in distance covered of 1.39 m. Of the 34 scores in the PLA
group, 9 (26.5%) scores experienced a performance improvement greater than the entire study average.
The proprietary milk protein concentrate group (n = 24) reported an average increase in distance
covered of 4.74 m. Of the 24 scores in the proprietary milk protein concentrate group, 14 (58.3%) scores
experienced a performance improvement greater than the entire study average. Dotted line = average
change in 6-min walk distance for entire study cohort. Black horizontal bars = average change in 6-min
walk distance for each study group.

3.6. Clinical Safety and Cartilage Breakdown
No significant group × time interactions were found for any of the measured variables (Table 5).
Significant within-group changes were noted for a small number of variables but in all instances,
the values fell within normal clinical reference ranges. No significant group × time interaction effect
(95% CI on the difference between groups: −38 to 33 ng/MP, p = 0.89) was identified for changes in
cartilage oligomeric matrix protein (COMP). Furthermore, no within-group changes in COMP data
across time were seen for PLA (Baseline: 208 ± 93 vs. Post: 206 ± 77 ng/MP, p = 0.70) and MP (Baseline:
206 ± 90 vs. Post: 213 ± 88 ng/MP, p = 0.61).
Table 5. Serum and Whole Blood Clinical Markers of Safety.
Variables

n

Baseline
(Week 0)

Post
(Week 8)

Within
p Value

Between-Group Comparison
Mean Difference

PLA
MP

34
24

5.54 ± 1.41
5.85 ± 1.43

White Blood Cell Count (cells/L)
5.20 ± 1.48
0.045
−0.14 ± 0.37
0.56
5.65 ± 1.24

PLA
MP

34
24

4.89 ± 0.43
4.69 ± 0.42

Red Blood Cell Count (cells/L)
4.91 ± 0.51
0.57
0.003 ± 0.06
4.71 ± 0.35
0.72

PLA
MP

34
24

14.7 ± 1.4
14.3 ± 1.6

14.5 ± 1.4
14.1 ± 1.3

PLA
MP

34
24

41.6 ± 3.0
40.7 ± 4.4

42.3 ± 3.6
41.2 ± 3.4

Hematocrit (%)
0.03
0.21

89.7 ± 10.9
95.2 ± 8.9

Glucose (mg/dL)
0.07
−0.51 ± 2.3
0.01

PLA
MP

34
24

86.4 ± 7.0
91.3 ± 7.4

Hemoglobin (g/dL)
0.23
2.86 ± 1.98
0.11

0.06 ± 0.18

95% CI

p Value

(−0.90, 0.61)

0.71

(−0.12, 0.12)

0.95

(−1.12, 6.83)

0.16

(−0.30, 0.41)

0.75

(−5.02, 4.0)

0.82
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Table 5. Cont.
Variables

PLA
MP

n

34
24

Within
p Value

Between-Group Comparison

Baseline
(Week 0)

Post
(Week 8)

14.5 ± 4.3
15.7 ± 4.7

Blood Urea Nitrogen (BUN) (mg/dL)
14.9 ± 4.0
0.66
0.70 ± 1.09
15.3 ± 4.0
0.63

95% CI

p Value

(−1.48, 2.88)

0.52

(−0.02, 0.08)

0.23

(−2.70, 2.51)

0.94

(−1.71, 1.05)

0.64

(−0.16, 0.13)

0.84

(−1.16, 2.00)

0.59

(−1.84, 0.40)

0.20

(−0.15, 0.19)

0.79

−0.09 ± 0.1

(−0.29, 0.10)

0.35

0.16 ± 0.08

(−0.14, 0.17)

0.83

(−0.24, 0.03)

0.13

(−0.06, 0.20)

0.30

(−0.05, 0.18)

0.25

(−3.7, 3.6)

0.98

(−2.6, 2.3)

−0.92

(−6.3, 1.0)

0.16

(−13.0, 8.6)

0.68

(−48.5, 11.6)

0.23

(−1.10, 6.81)

0.15

(−9.6, 2.6)

0.26

(−9.3, 12.3)

0.78

Mean Difference

PLA
MP

34
24

0.87 ± 0.14
0.88 ± 0.17

Creatinine (mg/dL)
0.91 ± 0.14
0.04
0.03 ± 0.02
0.88 ± 0.17
0.71

PLA
MP

34
24

16.8 ± 4.6
17.9 ± 4.9

16.3 ± 3.3
17.5 ± 4.5

BUN: Creatinine Ratio
0.58
−0.096 ± 1.30
0.71

PLA
MP

34
24

141.7 ± 2.0
141.3 ± 2.3

140.3 ± 2.6
140.2 ± 1.9

Sodium (mEq/L)
0.009
−0.33 ± 0.69
0.012

PLA
MP

34
24

4.4 ± 0.25
4.3 ± 0.26

4.4 ± 0.27
4.3 ± 0.23

Potassium (mEq/L)
0.62
−0.014 ± 0.07
0.72

PLA
MP

34
24

102.5 ± 2.2
101.9 ± 2.2

102.6 ± 3.0
101.6 ± 1.8

Chloride (mEq/L)
0.87
0.42 ± 0.79
0.54

PLA
MP

34
24

24.1 ± 1.8
23.5 ± 2.1

Carbon Dioxide (mEq/L)
23.8 ± 2.3
0.48
−0.72 ± 0.56
23.9 ± 2.3
0.28

PLA
MP

34
24

9.26 ± 0.23
9.28 ± 0.33

9.27 ± 0.27
9.26 ± 0.34

Calcium (mg/dL)
0.92
0.02 ± 0.08
0.78

PLA
MP

34
24

6.99 ± 0.42
9.81 ± 0.43

6.92 ± 0.37
6.94 ± 0.44

Protein (g/dL)
0.30
0.74

PLA
MP

34
24

4.47 ± 0.28
4.53 ± 0.33

4.48 ± 0.18
4.52 ± 0.28

Albumin (g/dL)
0.79
0.95

PLA
MP

34
24

2.52 ± 0.32
2.39 ± 0.23

2.44 ± 0.35
2.42 ± 0.32

Globulin (g/dL)
0.09
−0.11 ± 0.07
0.58

PLA
MP

34
24

1.81 ± 0.24
1.92 ± 0.21

Albumin: Globulin Ratio
1.88 ± 0.28
0.12
0.07 ± 0.06
1.91 ± 0.30
0.89

PLA
MP

34
24

0.50 ± 0.20
0.60 ± 0.34

0.44 ± 0.20
0.48 ± 0.25

PLA
MP

34
24

70.7 ± 17.3
65.5 ± 18.7

Alkaline Phosphatase (IU/L)
72.3 ± 18.2
0.21
−0.04 ± 1.84
67.2 ± 20.6
0.23

PLA
MP

34
24

22.4 ± 8.7
19.7 ± 4.7

Aspartate Aminotransferase (U/L)
23.7 ± 14.7
0.83
−0.13 ± 1.23
20.8 ± 8.2
0.56

PLA
MP

34
24

23.7 ± 14.7
20.8 ± 8.2

Alanine Aminotransferase (U/L)
20.0 ± 8.9
0.02
−2.65 ± 1.84
19.8 ± 7.7
0.17

Bilirubin (mg/dL)
0.03
0.07 ± 0.06
0.03

PLA
MP

34
24

178 ± 31
196 ± 34

Total Cholesterol (mg/dL)
174 ± 31
0.21
−2.2 ± 5.4
194 ± 40
0.72

PLA
MP

34
24

110 ± 81
119 ± 83

90 ± 74
118 ± 81

PLA
MP

34
24

58 ± 19
59 ± 15

57 ± 20
56 ± 18

PLA
MP

34
24

19.8 ± 10.6
23.9 ± 16.7

PLA
MP

34
24

95 ± 30
113 ± 23

Triglycerides (mg/dL)
0.002
−18.4 ± 15.0
0.91
HDL Cholesterol (mg/dL)
0.79
2.86 ± 2.0
0.04

VLDL Cholesterol (mg/dL)
16.1 ± 9.1
0.003
−3.48 ± 3.0
23.5 ± 16.2
0.92
99 ± 27
115 ± 28

LDL Cholesterol (mg/dL)
0.37
1.50 ± 5.4
0.62

PLA = Placebo; MP = proprietary milk protein concentrate. L = Liters; g = grams; dL = deciliter; mg = milligrams;
mEq = milliequivalents; IU = International Units; U = Units of catalyzed enzyme; HDL = High-density lipoprotein;
VLDL = Very low-density lipoprotein; LDL = Low-density lipoprotein; 95% CI = 95% confidence interval of the
difference between MP and PLA. Within p-value derived from factorial ANOVA with repeated measures on time.
Between-group p-values were calculated using independent t-tests using the delta value (week 8–week 0).
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4. Discussion
Using a randomized, double-blind, placebo-controlled design, the purpose of the present study
was to assess the impact of a proprietary milk protein concentrate from hyperimmunized cows
(proprietary milk protein concentrate) on changes in joint health, joint pain, physical function, walking
performance, quality of life and other measures of affect in non-osteoarthritic men and women who
reported having mild to moderate knee pain during physical activity. The primary findings of this
investigation indicate that treatment with proprietary milk protein concentrate resulted in significantly
greater improvements in several components within the WOMAC assessment, walking performance,
as well as self-reported levels of pain, discomfort, stiffness and stability (see Figure 4).

Figure 4. Percentage change in PLA and MP for WOMAC—Physical Function, WOMAC—Total
Score, Low-Back Health, Neck Health and 6-Minute Walk Test Performance. Grey bars = PLA;
Black bars = MP (proprietary milk protein concentrate).

Previous research has established the ability of various dairy products to improve joint pain
and associated symptoms in osteoarthritic and rheumatoid arthritic populations [15], improve
cholesterol [9] and reduce inflammation [10,11]. While these studies are encouraging, they did not
measure potential effects on functional endpoints in non-osteoarthritic individuals.
To date, only two studies have used rigorous study designs to assess the potential efficacy of
proprietary milk protein concentrate, a concentrated milk protein produced from hyperimmunized
cows. Colker et al. [16] supplemented 31 adults who were previously diagnosed with knee
osteoarthritis with either a placebo or a proprietary milk protein concentrate in a randomized,
double-blind manner. All participants completed similar assessments to those in the present study
(VAS, WOMAC, etc.) at the beginning and after six weeks of supplementation. In agreement
with our findings, significant treatment effects in favor of proprietary milk protein concentrate
supplementation were found for knee pain, sport function and quality of life. An additional
investigation by Zenk et al. [17] compared the impact of ingesting proprietary milk protein concentrate,
glucosamine sulfate or a placebo in men and women (range: 34–86 years) previously diagnosed with
osteoarthritis. As in the present study, osteoarthritis symptoms assessed via WOMAC improved in the
proprietary milk protein concentrate group, with similar but less pronounced effects occurring in the
glucosamine group. A key difference between the present study and these previous investigations was
our use of non-osteoarthritic individuals as subjects. Indeed, improvements in joint health were noted
in our non-osteoarthritic participants, along with additional noteworthy findings. First, we reported
for the first time, perceived improvements in overall back and neck health as well as significant
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improvements in six minute walk performance in subjects who supplemented with the proprietary
milk protein concentrate. While we recognize that other forms of exercise may or may not yield similar
outcomes, considering the critical role of walking performance on quality of life in present day society,
the positive changes reported in the present study are quite encouraging. Finally, in agreement with
previous studies, milk protein concentrate supplementation was well tolerated and all markers of
safety remained within clinically accepted normative values throughout the intervention. Furthermore,
no adverse events occurred throughout the study.
Considering the wide array of beneficial changes in the WOMAC and VAS data, we were
somewhat surprised to find no changes in cartilage oligomeric matrix protein (COMP), a marker
of cartilage breakdown. COMP is found in human chondrocytes and is known to increase after knee
injury and in early stages of osteoarthritis [22,23] and COMP levels have been shown to increase in
endurance-trained runners [24]. Data from the present study, however, did not uncover any significant
changes in COMP from supplementation. This is likely due to the fact that our participants had
not recently suffered some form of joint injury, were not diagnosed with osteoarthritis and were not
currently completing high volumes of endurance training. It is possible that prescribing some form
of exercise program may lead to changes in COMP levels but this remains beyond the scope of our
study protocol.
A few key strengths of our study design are worth highlighting. First, the present investigation
is the largest randomized, double-blind, placebo-controlled study to date on concentrated milk
protein derived from milk produced in hyperimmunized cows (proprietary milk protein concentrate).
The previous work of Zenk and Colker used 10–15 participants per group while our study finished
with 58 participants. Additionally, the participants recruited in the present study were younger and
were required to have no pain at rest and only mild to moderate pain after physical exertion (i.e., had no
previous medical diagnosis of arthritis). In addition, the Zenk and Colker studies reported on changes
in concentrated milk protein ingestion in subjects that had already been diagnosed with osteoarthritis
in at least one joint, making it tempting to speculate that a larger window of improvement existed in
these previous studies as opposed to our cohort. This key point also speaks to the potential impact the
present findings may have on the much larger population of people beginning to experience knee pain
but not yet diagnosed with arthritis. Finally, the present study was the first to examine and report on
improvements in a measure of physical performance (6-minute walk) as well as changes in a biomarker
of cartilage breakdown.
We acknowledge our study has limitations. For starters, our results are specific to a middle-aged
population with no resting knee pain, no previous diagnosis of joint disease and only mild to moderate
joint pain with physical exertion. Thus, extrapolating our findings to other populations should be made
with caution. The duration of the present study was only eight weeks and while this timeline extends
previous findings, a longer study duration (16–24 weeks) is recommended in future studies. Finally,
more accurate monitoring of physical activity is recommended to determine if early improvements in
function and pain lead to natural increases in habitual physical activity and quality of life.
In conclusion, eight weeks of supplementing with a proprietary milk protein concentrate
(proprietary milk protein concentrate) results in significant improvements in walking performance
as well as several individual components of the WOMAC, the physical function subscale and the
total WOMAC score. In addition, proprietary milk protein concentrate also improved self-reported
indications of pain, discomfort, stiffness, soreness, function and quality of life.
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